Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Medco Audit Finds “Minor” Compliance Problems; How “Isolated” Are They?

  • News

Executive Summary

Medco has uncovered "minor policy violations" in an ongoing corporate-wide compliance audit initiated in April, the company disclosed during a Sept. 29 conference call discussing the Philadelphia U.S. Attorney's lawsuit against the company

You may also be interested in...



Caremark PCS Merger Wins Big Customer; Blues Move FEP Mail From Medco

Caremark will take over the mail service pharmacy program for the Blue Cross/Blue Shield Association Federal Employees Program effective Jan. 1

Caremark PCS Merger Wins Big Customer; Blues Move FEP Mail From Medco

Caremark will take over the mail service pharmacy program for the Blue Cross/Blue Shield Association Federal Employees Program effective Jan. 1

Medco Eyeing “Vigorous” Public Relations Defense To False Claims Act Suit

Medco is planning an aggressive public relations defense to coincide with its legal fight against Philadelphia's U.S. Attorney

Table

View full table

Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS042575

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By